Related Experiment Video
Updated: Jul 27, 2025

Quantification of Monocyte Chemotactic Activity In Vivo and Characterization of Blood Monocyte Derived Macrophages
Published on: August 12, 2019
Endothelial CCRL2 induced by disturbed flow promotes atherosclerosis via chemerin-dependent β2 integrin activation in
Chaojun Tang1,2,3,4,5, Guona Chen1, Fan Wu1,6
1Cyrus Tang Medical Institute, Soochow University, Rm 509, Bldg 703, 199 Ren'ai Road, Suzhou 215123, China.
Insights
Disturbed blood flow upregulates atypical chemokine receptor 5 (CCRL2), promoting atherosclerosis. This novel pathway involves chemerin and beta-2 integrin, offering new therapeutic targets for preventing plaque formation.
Area of Science:
- Cardiovascular Biology
- Immunology
- Molecular Medicine
Background:
- Atherosclerosis is driven by leukocyte recruitment to arterial walls, particularly in areas of disturbed flow (d-flow).
- Atypical chemokine receptors (ACKRs), including ACKR5 (CCRL2), are implicated in inflammatory processes.
- CCRL2 is upregulated in endothelial cells under atherosclerotic conditions and d-flow.
Purpose of the Study:
- To investigate the role of CCRL2 and its ligand chemerin in atherosclerosis.
- To elucidate the underlying molecular mechanisms of CCRL2-mediated leukocyte recruitment in d-flow areas.
Main Methods:
- Analysis of single-cell RNA sequencing data from mouse carotid arteries under d-flow.
- Utilized CCRL2-/-ApoE-/- mice fed a high-fat diet to assess plaque formation.
- Investigated chemerin's interaction with beta-2 integrin using biochemical assays and proximity ligation assays.
Main Results:
- CCRL2 expression is increased in endothelial cells under d-flow and atherosclerotic conditions.
- CCRL2 deficiency reduced atherosclerotic plaque formation in ApoE-/- mice, especially in d-flow regions.
- Chemerin, via its protein disulfide isomerase-like activity, activates beta-2 integrin, enhancing monocyte adhesion and ERK1/2 phosphorylation.
- Elevated serum chemerin levels were observed in patients with acute atherothrombotic stroke.
Conclusions:
- Disturbed flow-induced CCRL2 promotes atherosclerotic plaque development through a novel CCRL2-chemerin-beta-2 integrin axis.
- This pathway represents a potential therapeutic target for atherosclerosis prevention and treatment.
Aims:
Chemoattractants and their cognate receptors are essential for leucocyte recruitment during atherogenesis, and atherosclerotic plaques preferentially occur at predilection sites of the arterial wall with disturbed flow (d-flow). In profiling the endothelial expression of atypical chemoattractant receptors (ACKRs), we found that Ackr5 (CCRL2) was up-regulated in an endothelial subpopulation by atherosclerotic stimulation. We therefore investigated the role of CCRL2 and its ligand chemerin in atherosclerosis and the underlying mechanism.
Methods And Results:
By analysing scRNA-seq data of the left carotid artery under d-flow and scRNA-seq datasets GSE131776 of ApoE-/- mice from the Gene Expression Omnibus database, we found that CCRL2 was up-regulated in one subpopulation of endothelial cells in response to d-flow stimulation and atherosclerosis. Using CCRL2-/-ApoE-/- mice, we showed that CCRL2 deficiency protected against plaque formation primarily in the d-flow areas of the aortic arch in ApoE-/- mice fed high-fat diet. Disturbed flow induced the expression of vascular endothelial CCRL2, recruiting chemerin, which caused leucocyte adhesion to the endothelium. Surprisingly, instead of binding to monocytic CMKLR1, chemerin was found to activate β2 integrin, enhancing ERK1/2 phosphorylation and monocyte adhesion. Moreover, chemerin was found to have protein disulfide isomerase-like enzymatic activity, which was responsible for the interaction of chemerin with β2 integrin, as identified by a Di-E-GSSG assay and a proximity ligation assay. For clinical relevance, relatively high serum levels of chemerin were found in patients with acute atherothrombotic stroke compared to healthy individuals.
Conclusions:
Our findings indicate that d-flow-induced CCRL2 promotes atherosclerotic plaque formation via a novel CCRL2-chemerin-β2 integrin axis, providing potential targets for the prevention or therapeutic intervention of atherosclerosis.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Atherosclerosis I: Introduction
Inflammation
Intracellular Signaling Affects Focal Adhesions
Some...
Regulation of Angiogenesis and Blood Supply
Coronary Artery Disease I: Introduction

